You are here: Industry Insights > Innovent Biologics

News List

Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024 PRNewswire
December 09, 2024
announced updated Phase 1 study results of IBI343, an innovative anti-Innovent BiologicsCLDN18.2 ADC, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) during an oral presentation at the ESMO Asia Congress 2024.
Innovent Announces First Subject Dosed in Trial of Anti-IL-23 Monoclonal Antibody americanpharmaceuticalreview
September 02, 2020
Innovent Biologics announced the Phase I clinical study (CIBI112A101) of recombinant anti-interleukin 23p19 subunit antibody injection (IBI112) has completed the first healthy subject dosing in China.
Eli Lilly expands Tyvyt collaboration with Innovent Biologics pharmaceutical-technology
August 20, 2020
Eli Lilly has agreed to a global expansion of its strategic collaboration with Innovent Biologics for Tyvyt (sintilimab injection), which the partners jointly develop in China.
Innovent Biologics enters drug development deal with Roche pharmaceutical-technology
June 10, 2020
Chinese biopharmaceutical firm Innovent Biologics has entered a strategic research and development partnership with Roche for various cell therapies and bispecific antibodies.
Innovent Biologics Announces First Patient Dosed in the Pivotal Registrational Trial of Pemigatinib in Patients with Advanced Cholangiocarcinoma in China prnasia
March 04, 2020
The objective of this study is to evaluate the efficacy and safety of pemigatinib in patients with advanced cholangiocarcinoma with FGFR2 fusions or rearrangements who have progressed from at least one prior systemic therapy in China.
Innovent Biologics, Eli Lilly has announced that IBI301 has met pre-defined primary endpoints biospectrumasia
May 09, 2019
The details of these studies will be disclosed in future publications in scientific journals and conferences.
Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody en-cphi.cn
March 21, 2019
Innovent Biologics announced that the first patient has been successfully dosed in a Phase IIa clinical study of IBI306...
Incyte agrees to licence three products to Innovent Biologics pharmaceutical-technology
December 19, 2018
US-based pharmaceutical company Incyte has signed a strategic collaboration agreement to out-licence three clinical-stage products to China-based Innovent Biologics.....
Innovent Biologics completed US$150 million Series E round financing biospace
April 27, 2018
Innovent Biologics, Inc., a leading biotech company in China, is pleased to announce the completion of its US$150 million Series E round financing.